“CELLMED Research GmbH, founded in 2006, is an Austrian Life Science Company focused on research and development of cellular therapies, in particular on the manufacturing and clinical application of cellular immunotherapy for the treatment of solid tumors. A clinical study in phase I / IIa on the safety of PROCURE® for the treatment of ovarian cancer is currently under way. PROCURE® is composed of autologous, double loaded dendritic cells that are patented in Europe. Corresponding patents in USA and Japan have been filed.
In addition to CELLMED as the parent enterprise the company consists of two fully owned subsidiaries: LIFE RESEARCH Technologies GmbH (responsible for clinical research on cellular immunotherapy for the treatment of cancer) and Cellpro Danube GmbH (responsible for the manufacturing and control of clinical test material). To fulfill the high quality standards for cellular therapy Cellpro Danube has built a new, modern, officially authorized cleanroom production facility in compliance with the stringent international GMP (GMP = Good Manufacturing Practice) guidelines.”